Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A

Arthritis and Rheumatism

Volumn 63, Issue 11, 2011, Pages 3586-3597

  Chrysanthopoulou, Akrivi ^a   Mitroulis, Ioannis ^a   Kambas, Konstantinos ^a   Skendros, Panagiotis ^a   Kourtzelis, Ioannis ^a,b   Vradelis, Stergios ^a   Kolios, George ^a   Aslanidis, Spyros ^c   Doumas, Michael ^c   Ritis, Konstantinos ^a,d  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Aristotle University and Hippokration General Hospital   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS; UPREGULATION; WESTERN BLOTTING;

CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE I; COLON; CONNECTIVE TISSUE GROWTH FACTOR; FIBROSIS; HUMANS; MYOFIBROBLASTS; RECEPTOR, ENDOTHELIN A; RECEPTOR, PAR-1; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; THROMBIN; THROMBOPLASTIN; UP-REGULATION;

EID: 80053893686     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30586     Document Type: Article

References (46)

1. Krieg T, Takehara K,. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl 3: iii14-8.
2. Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45: 346-54. (Pubitemid 32738740)
3. Denton CP, Lapadula G, Mouthon L, Muller-Ladner U,. Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 2009; 48 Suppl 3: iii32-5.
4. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67. (Pubitemid 46348510)
5. Holbourn KP, Acharya KR, Perbal B,. The CCN family of proteins: structure-function relationships. Trends Biochem Sci 2008; 33: 4613.
6. Chen CC, Lau LF,. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009; 41: 771-83.
7. Shi-Wen X, Leask A, Abraham D,. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008; 19: 133-44. (Pubitemid 351382279)
8. Yu CC, Hsu MJ, Kuo ML, Chen RF, Chen MC, Bai KJ, et al. Thrombin-induced connective tissue growth factor expression in human lung fibroblasts requires the ASK1/JNK/AP-1 pathway. J Immunol 2009; 182: 7916-27.
9. Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 159: 1383-95. (Pubitemid 32947968)
10. Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007; 357: 1210-20. (Pubitemid 47443180)
11. Shi-Wen X, Pennington D, Holmes A, Leask A, Bradham D, Beauchamp JR, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000; 259: 213-24.
12. Leask A, Parapuram SK, Shi-Wen X, Abraham DJ,. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 2009; 3: 89-94.
13. Bogatkevich GS, Ludwicka-Bradley A, Silver RM,. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009; 60: 3455-64.
14. Liu S, Shi-wen X, Abraham DJ, Leask A,. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum 2011; 63: 239-46.
15. Guiducci S, Giacomelli R, Cerinic MM,. Vascular complications of scleroderma. Autoimmun Rev 2007; 6: 520-3. (Pubitemid 47374612)
16. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M,. Mechanisms of vascular damage in SScâimplications for vascular treatment strategies. Rheumatology (Oxford) 2008; 47 Suppl 5: v18-20.
17. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S,. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-2. (Pubitemid 120015147)
18. Teder P, Noble PW,. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2000; 23: 7-10. (Pubitemid 30597089)
19. Abraham D, Dashwood M,. Endothelinârole in vascular disease. Rheumatology (Oxford) 2008; 47 Suppl 5: v23-4.
20. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsetsâa marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838-44. (Pubitemid 24312644)
21. Kim HS, Park MK, Kim HY, Park SH,. Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis. Clin Rheumatol 2010; 29: 247-54.
22. Cambrey AD, Harrison NK, Dawes KE, Southcott AM, Black CM, du Bois RM, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 1994; 11: 439-45.
23. Shiwen X, Leask A, Abraham DJ, Fonseca C,. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma [published erratum appears in Eur J Clin Invest 2009;39:630]. Eur J Clin Invest 2009; 39 Suppl 2: 19-26.
24. Rosato E, Molinaro I, Borghese F, Rossi C, Pisarri S, Salsano F,. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 2010; 37: 2531-9.
25. Korn JH, Mayes M, Matucci-Cerinic M, Rainisio M, Pope J, Hachulla E, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-93. (Pubitemid 39643947)
26. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70: 32-8.
27. Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakian C, Yaici A, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49: 490-500.
28. i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol 2005; 175: 5403-11. (Pubitemid 41460515)
29. Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, et al. C5a and TNF-α up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 2008; 180: 7368-75.
30. Cerinic MM, Valentini G, Sorano GG, D'Angelo S, Cuomo G, Fenu L, et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003; 32: 285-95. (Pubitemid 36459278)
31. Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L, et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 1997; 36: 1045-50.
32. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53: 506-10. (Pubitemid 24256979)
33. Chen D, Dorling A,. Critical roles for thrombin in acute and chronic inflammation. J Thromb Haemost 2009; 7 Suppl 1: 122-6.
34. Schaffner F, Ruf W,. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008; 34: 147-53.
35. Ohba T, McDonald JK, Silver RM, Strange C, LeRoy EC, Ludwicka A,. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor α-receptor. Am J Respir Cell Mol Biol 1994; 10: 405-12.
36. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A,. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via proteolytically activated receptor-1 and protein kinase C-dependent pathway. J Biol Chem 2001; 276: 45184-92.
37. Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, Akter T, van Ryn J, Silver RM,. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 2011; 63: 1416-25.
38. Koch AE, Distler O,. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007; 9 Suppl 2: S3.
39. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B,. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-7. (Pubitemid 39507134)
40. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 2707-19. (Pubitemid 38691860)
41. Shi-Wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD, et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 2007; 26: 625-32. (Pubitemid 350186096)
42. Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, Esteban V, Sanchez-Lopez E, Plaza JJ, et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-β, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 2005; 97: 125-34. (Pubitemid 41033468)
43. Shi-Wen X, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006; 26: 5518-27. (Pubitemid 44036217)
44. Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 2010; 49: 1336-45.
45. Kambas K, Chrysanthopoulou A, Kourtzelis I, Skordala M, Mitroulis I, Rafail S, et al. Endothelin-1 signaling promotes fibrosis in vitro in a bronchopulmonary dysplasia model by acti-vating the extrinsic coagulation cascade. J Immunol 2011; 186: 6568-75.
46. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G,. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-16. (Pubitemid 47339255)